Mandate

Vinge advises STMicroelectronics on its acquisition of a majority stake in Norstel AB

February 07, 2019 M&A

Vinge has advised the French-Italian electronics and semiconductor manufacturer STMicroelectronics in connection with STMicroelectronics entering into an agreement to acquire a majority stake in the Swedish silicon carbide wafer manufacturer Norstel AB.

Upon completion of the transaction (which is subject to conditions), STMicroelectronics will acquire 55% of Norstel AB, with an option to acquire the remaining 45% subject to certain conditions. If such option is exercised, it will result in a total consideration of USD 137,500,000 for 100% of Norstel AB.

Vinge’s team consisted of, among others, Christina Kokko, Ulrich Ziche, Linda Sengul and Desirée Sjöblom (Corporate and M&A), Gu Qun, Gabriella Fossum, Jasmin Draszka-Ali and Hayaat Ibrahim (Regulatory and Compliance), Klara Secher (IP), Sophia Holm and Lova Unge (Employment), Nicklas Thorgerzon (IT), Axel Jansson and Anna Åhlberg (Banking and Financing), Anne Wijkman (Real Estate/Lease Agreements), Trine Osen Bergkvist (Competition), Fredrika Hjelmberg (Commercial Agreements), Hampus Olsson (Environment) and Jessica Öijer (VDR assistant).
 

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025